{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T10:15:39Z","timestamp":1785838539246,"version":"3.56.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,10,30]],"date-time":"2018-10-30T00:00:00Z","timestamp":1540857600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012634","name":"Novocure, Israel","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012634","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pancreatology"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.pan.2018.10.004","type":"journal-article","created":{"date-parts":[[2018,10,17]],"date-time":"2018-10-17T02:21:57Z","timestamp":1539742917000},"page":"64-72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":75,"title":["Tumor treating fields in combination with gemcitabine or gemcitabine plus nab-paclitaxel in pancreatic cancer: Results of the PANOVA phase 2 study"],"prefix":"10.1016","volume":"19","author":[{"given":"Fernando","family":"Rivera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Benavides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Gallego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3594-1084","authenticated-orcid":false,"given":"Carmen","family":"Guillen-Ponce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Lopez-Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"K\u00fcng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.pan.2018.10.004_bib1","first-page":"69","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"Ca - Cancer J Clin"},{"issue":"1","key":"10.1016\/j.pan.2018.10.004_bib2","first-page":"7","article-title":"Cancer statistics","volume":"66","author":"Siegel","year":"2016","journal-title":"Ca - Cancer J Clin"},{"issue":"19","key":"10.1016\/j.pan.2018.10.004_bib3","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1016\/j.pan.2018.10.004_bib4","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.pan.2018.10.004_bib5","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nrclinonc.2015.53","article-title":"Pancreatic cancer: from state-of-the-art treatments to promising novel therapies","volume":"12","author":"Garrido-Laguna","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"issue":"23","key":"10.1016\/j.pan.2018.10.004_bib6","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of Tumor-Treating Fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial","volume":"318","author":"Stupp","year":"2017","journal-title":"J\u00a0Am Med Assoc"},{"issue":"14","key":"10.1016\/j.pan.2018.10.004_bib7","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1016\/j.ejca.2012.04.011","article-title":"NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality","volume":"48","author":"Stupp","year":"2012","journal-title":"Eur J Canc"},{"issue":"9","key":"10.1016\/j.pan.2018.10.004_bib8","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1158\/0008-5472.CAN-04-0083","article-title":"Disruption of cancer cell replication by alternating electric fields","volume":"64","author":"Kirson","year":"2004","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.pan.2018.10.004_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0125269","article-title":"Tumor treating fields perturb the localization of septins and cause aberrant mitotic exit","volume":"10","author":"Gera","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.pan.2018.10.004_bib10","doi-asserted-by":"crossref","first-page":"18046","DOI":"10.1038\/srep18046","article-title":"Mitotic spindle disruption by alternating electric fields leads to improper chromosome segregation and mitotic catastrophe in cancer cells","volume":"5","author":"Giladi","year":"2015","journal-title":"Sci Rep"},{"issue":"24","key":"10.1016\/j.pan.2018.10.004_bib11","doi-asserted-by":"crossref","first-page":"10152","DOI":"10.1073\/pnas.0702916104","article-title":"Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors","volume":"104","author":"Kirson","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"suppl 19","key":"10.1016\/j.pan.2018.10.004_bib12","article-title":"TTFields reduce cancer cell clonogenic potential through abnormal chromosome segregation during mitosis","volume":"74","author":"Schneiderman","year":"2014","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.pan.2018.10.004_bib13","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1517\/13543784.2011.583236","article-title":"Tumor treating fields: concept, evidence and future","volume":"20","author":"Pless","year":"2011","journal-title":"Expet Opin Invest Drugs"},{"issue":"1","key":"10.1016\/j.pan.2018.10.004_bib14","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.pan.2013.11.009","article-title":"Mitotic disruption and reduced clonogenicity of pancreatic cancer cells in\u00a0vitro and in\u00a0vivo by tumor treating fields","volume":"14","author":"Giladi","year":"2014","journal-title":"Pancreatology"},{"issue":"suppl 3","key":"10.1016\/j.pan.2018.10.004_bib15","article-title":"A\u00a0simulation-based study on the distribution of TTFields in the body when treating pancreatic cancer","volume":"28","author":"Wenger","year":"2017","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.pan.2018.10.004_bib16","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.lungcan.2013.06.025","article-title":"A\u00a0phase I\/II trial of Tumor Treating Fields (TTFields) therapy in combination with pemetrexed for advanced non-small cell lung cancer","volume":"81","author":"Pless","year":"2013","journal-title":"Lung Canc"},{"key":"10.1016\/j.pan.2018.10.004_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2018.07.018","article-title":"Tumor Treating Fields in combination with paclitaxel in recurrent ovarian carcinoma: results of the INNOVATE pilot study","author":"Vergote","year":"2018","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.pan.2018.10.004_bib18","first-page":"S329","article-title":"OA22.01 STELLAR - interim results of a phase 2 trial of TTFields with chemotherapy for first line treatment of malignant mesothelioma","volume":"12","author":"Grosso","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.pan.2018.10.004_bib19","series-title":"Proceedings of the 109th annual meeting of the american association for cancer research; 2018 apr 14-18; Chicago, Illinois. Philadelphia (PA)","article-title":"TTFields and radiosurgery for 1 to 10 brain metastases from NSCLC in the phase III METIS study","author":"Mehta","year":"2018"},{"issue":"Suppl 4","key":"10.1016\/j.pan.2018.10.004_bib20","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/j.seminoncol.2014.03.011","article-title":"Characterization and management of dermatologic adverse events with the NovoTTF-100A System, a novel anti-mitotic electric field device for the treatment of recurrent glioblastoma","volume":"41","author":"Lacouture","year":"2014","journal-title":"Semin Oncol"},{"issue":"17","key":"10.1016\/j.pan.2018.10.004_bib21","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1001\/jama.2016.4324","article-title":"Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 Months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial","volume":"315","author":"Hammel","year":"2016","journal-title":"J\u00a0Am Med Assoc"},{"issue":"9","key":"10.1016\/j.pan.2018.10.004_bib22","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1001\/jamaoncol.2016.0585","article-title":"Evaluation of pancreatic cancer clinical trials and benchmarks for clinically meaningful future trials: a systematic review","volume":"2","author":"Rahib","year":"2016","journal-title":"JAMA Oncol"}],"container-title":["Pancreatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1424390318306987?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1424390318306987?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T16:07:21Z","timestamp":1761408441000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1424390318306987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S1424390318306987"],"URL":"https:\/\/doi.org\/10.1016\/j.pan.2018.10.004","relation":{},"ISSN":["1424-3903"],"issn-type":[{"value":"1424-3903","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor treating fields in combination with gemcitabine or gemcitabine plus nab-paclitaxel in pancreatic cancer: Results of the PANOVA phase 2 study","name":"articletitle","label":"Article Title"},{"value":"Pancreatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pan.2018.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier B.V. on behalf of IAP and EPC.","name":"copyright","label":"Copyright"}]}}